收案條件

Men aged between 45 - 75 years
Life expectancy \> 10 years upon recruitment
Able to understand the trial and can provide informed and written consent, dated and signed before the enrollment and before any exam required by the trial
Localized low or intermediate risk prostate cancer diagnosed on MRI-Ultrasound fusion targeted biopsy
Organ-confined prostate cancer on MRI
PSA \< 20 ng/mL
MRI visible lesion present and size ≤15mm, with targeted biopsy showing:
ISUP grade group 2 or 3, or
ISUP grade group 1 with tumor size ≥10mm

Patients not fit for general or spinal anaesthesia
Patients unfit for MRI exam or MR gadolinium contrast (e.g. estimated glomerular filtration rate (eGFR) of \<50 ml/min)
Patients with coagulopathy that cannot be corrected
Patients on anticoagulants or antiplatelets that cannot be stopped (Low dose Aspirin, e.g. 80-100mg, is acceptable and no need to stop before or during TMA treatment)
Patients with previous treatment of prostate cancer
Patients with prior pelvic radiotherapy for prostate cancer or other cancer
Patients with maximal length of target lesion \>15mm
Patients with MRI-visible or invisible lesion within 10mm from rectum or 10mm from sphincter on MRI
Patients with \>2 areas (MRI-visible or invisible) of prostate cancer
Patients with Gleason score 4+4 or any Gleason pattern 5 cancer
Patients with systematic cores showing any Gleason 4 pattern PCa which are not adjacent to the target lesions (1 core of pure Gleason 3 pattern PCa on systematic cores in contralateral lobe is acceptable)
Patients with definite cT3 or above disease on imaging (prostate capsular contact without definite extra-capsular extension is acceptable)
Patients with bladder pathology including bladder stone and bladder cancer
Patients with known urethral stricture
Patient with a suspected COVID-19 disease or an active SARS-CoV-2 infection.

收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。

針對局部前列腺癌的標靶微波消融（TMA）多中心試驗